As of Wednesday close, CVS Health Corporation’s (NYSE:CVS) stock was down -$0.58, moving down -0.81 percent to $71.41. The average number of shares traded per day over the past five days has been 10,211,681 shares. 4 times new highs have been achieved over the past 5 days, with a $1.17 gain in that time frame. In the last twenty days, the average volume was 8,714,330, while in the previous 50 days, it was 9,764,120.
Since last month, CVS stock rose 6.45%. Shares of the company fell to $65.05 on 09/07/23, the lowest level in the past month. A 52-week high of $104.83 was reached on 01/04/23 after having rallying from a 52-week low of $64.62. Since the beginning of this year, CVS’s stock price has dropped by -23.37% or -$21.78, and marked a new high 2 times. However, the stock has declined by -31.88% since its 52-week high.
CVS stock investors should be aware that CVS Health Corporation (CVS) stock had its last reported insider trading activity 49 days ago on Aug 03. Clark James David, the SVP, Cont & Chief Acct Officer of the company, disposed of 25,759 shares for $74.92 on Aug 03. It resulted in a $1,930,004 divestment by the insider. Lynch Karen S added 14,000 shares at an average price of $69.75 on May 03. The insider now owns 431,392 shares following the transaction. On Dec 15, EVP & General Counsel Moriarty Thomas M sold 137,466 shares at $98.36 apiece. The transaction was valued at $13,521,180.
Valuation Metrics
Right now, CVS Health Corporation (CVS) has a P/E ratio of about 31.35. The stock’s beta is 0.60. Besides these, the trailing price-to-sales (P/S) ratio of 0.27, the price-to-book (PB) ratio of 1.26, and the price-to-cash flow ratio of 5.12 may also be considered.
The latest dividend of $0.6050 per share was paid out, remained unchanged from last year’s $0.6050. On Thursday December 15 2022, a $0.0550 dividend increase was announced.
Financial Health
In the recent quarter, CVS Health Corporation’s quick ratio stood at 0.60, while its current ratio was 0.90, showing that the company is not able to pay off its debt. According to company report, the long-term debt-to-equity ratio for the recent quarter was 0.84, and the total debt-to-equity ratio was 0.88. On the profitability front, the trailing twelve-month gross margin is 39.00% percent. In the recent year, EBITDA margin amounted to 6.40%, whereas operating margins totaled 1.90%. Based on annual data, CVS earned $125.58 billion in gross profit and brought in $322.47 billion in revenue.
A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was 5.10%. Return on equity (ROE) for the past 12 months was 4.10%.
According to the earnings report, the company had a higher net income in the recent quarter than it did in the previous quarter. CVS’s revenue rose 9.32% to $85.28 billion during the quarter, while net income inched up to $88.92 billion. During the quarter, the company generated $4.34 billion in EBITDA. The liabilities of CVS Health Corporation were 177.07 billion at the end of its most recent quarter, and its total debt was $82.14 billion. The value of shareholders’ equity is $1.28 billion.
Technical Picture
This quick technical analysis looks at CVS Health Corporation’s (CVS) price momentum. With a historical volatility rate of 24.36%, the RSI 9-day stood at 66.58% on 20 September.
With respect to its five-day moving average, the current CVS Health Corporation price is up by +1.67% percent or $1.17. At present, CVS shares trade +6.50% above its 20-day simple moving average and -2.26% percent below its 100-day simple moving average. However, the stock is currently trading approximately +0.20% above its SMA50 and -29.75% below its SMA200.
Stochastic coefficient K was 90.57% and Stochastic coefficient D was 88.98%, while ATR was 1.46. Given the Stochastic reading of 87.72% for the 14-day period, the RSI (14) reading has been calculated as 59.94%. As of today, the MACD Oscillator reading stands at 1.34, while the 14-day reading stands at 2.95.
Analyst Ratings
Evercore ISI upgraded its rating on CVS Health Corporation (NYSE: CVS) to an Outperform in a note to investors on September 19, 2023. The analysts firm previously had an In-line rating on the stock.CVS Health Corporation (CVS) has been rated Overweight by analysts. According to 0 brokerage firms, CVS is a sell, and 6 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 2 analysts rate CVS Health Corporation stock as buy, with 19 recommending it as overweight.
With a median target price of $89.50, the current consensus forecast for the stock is $76.00 – $110.00. Based on these forecasts, analysts predict CVS Health Corporation (CVS) will achieve an average price target of $91.15.
